Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Lorinda, Simms"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9886acbf57f0bc41d9f3c6a77325893b
https://doi.org/10.1200/jco.22.02544
https://doi.org/10.1200/jco.22.02544
Autor:
Robert Paine, Robert Chasse, E Scott Halstead, Jay Nfonoyim, David J Park, Timothy Byun, Bela Patel, Guido Molina-Pallete, Estelle S Harris, Fiona Garner, Lorinda Simms, Sanjeev Ahuja, John L McManus, Debasish F Roychowdhury
Publikováno v:
Military medicine.
Introduction Granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein produced in the lung, is essential for pulmonary host defense and alveolar integrity. Prior studies suggest potential benefits in several pulmonary conditions, includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::382fbf3572ec75a094795cf132a8af44
https://pubmed.ncbi.nlm.nih.gov/36458916
https://pubmed.ncbi.nlm.nih.gov/36458916
Autor:
Sander Veldhuyzen van Zanten, Naoki Chiba, Alan Barkun, Carlo Fallone, Alain Farley, Alan Cockeram, Chrystian Dallaire, Lorinda Simms, Barbara Nicholls
Publikováno v:
Canadian Journal of Gastroenterology, Vol 17, Iss 9, Pp 533-538 (2003)
OBJECTIVE: To assess Helicobacter pylori eradication after one week dual ranitidine bismuth citrate-clarithromycin (RBC-C) or triple omeprazole, clarithromycin and amoxicillin (OCA) therapy.
Externí odkaz:
https://doaj.org/article/bbd71a0b92684e3fa1a65fb0b8854ec2
Publikováno v:
Canadian Journal of Gastroenterology, Vol 16, Iss 1, Pp 17-21 (2002)
BACKGROUND: Clinicians often rely on review material rather than analysis of primary research to guide therapy. Systematic reviews use methods to insure thoroughness and to minimize bias, but many clinicians are not familiar with systematic reviews a
Externí odkaz:
https://doaj.org/article/6e62cd01ac5442e4bfb88289ca155192
Publikováno v:
Journal of Thoracic Oncology. 6:978-982
Hazard ratios (HRs) are used commonly to report results from randomized clinical trials in oncology. However, they remain one of the most perplexing concepts for clinicians. A good understanding of HRs is needed to effectively interpret the medical l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c4efcd099c2f8d9819a2c840ac8adf
https://doi.org/10.1097/jto.0b013e31821b10ab
https://doi.org/10.1097/jto.0b013e31821b10ab
Autor:
Thomas Brodowicz, Frank V. Fossella, Frances A. Shepherd, Giorgio V. Scagliotti, Christian Manegold, Christoph C. Zielinski, Lorinda Simms, Katherine P. Sugarman, Johan Vansteenkiste, Chandra P. Belani
Publikováno v:
Journal of Thoracic Oncology. 6(1):64-70
Introduction: Recently, histology has emerged as a predictive factor for pemetrexed efficacy in non-small cell lung cancer (NSCLC). These analyses evaluate whether the differential efficacy of pemetrexed by NSCLC histology is reproducible and consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dbe1aa84c817df5001a1c7cf108195
Autor:
Mauro Papotti, Fred R. Hirsch, Anna Spreafico, Mary Dugan Wood, Silvia Novello, Lorinda Simms
Publikováno v:
Journal of Thoracic Oncology. 3:1468-1481
Introduction The importance of non-small cell lung cancer (NSCLC) histologic subtype has increased during the last few decades because of an unprecedented shift in epidemiology and an increasing number of target-specific chemotherapeutic agents. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996ceb275a0e89ace31a806f5f6a8680
https://doi.org/10.1097/jto.0b013e318189f551
https://doi.org/10.1097/jto.0b013e318189f551
Autor:
Lorinda Simms, Allen S. Melemed, Jane E. Latz, Hans Wildiers, Robert Paridaens, Celia Tosello Oliveira, Luc Dirix, Herlinde Dumez, Ana Alvarez, A Prové
Publikováno v:
Clinical Breast Cancer. 7:861-866
Background Pemetrexed and epirubicin are each active in patients with advanced/metastatic breast cancer (MBC). This phase I/II study evaluated these drugs as a combination regimen. Patients and Methods Women with locally advanced or MBC were enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb28c7e2d834a597cb46321a513ffbe5
https://doi.org/10.3816/cbc.2007.n.051
https://doi.org/10.3816/cbc.2007.n.051
Autor:
Lorinda Simms, Christopher Kaiser, Alexandra E. Eniu, Patrick Neven, Miguel Martin, Rodica M. Anghel, Nadia Harbeck, Antonio Llombart-Cussac, Romnee S. Clark, Mark Verrill, Allen S. Melemed, Doreen Ma, Jacques De Greve
Publikováno v:
Clinical Cancer Research. 13:3652-3659
Purpose: Pemetrexed has shown varied response rates in advanced breast cancer. This randomized, double-blind, phase II study was conducted to assess the efficacy and safety of two doses of pemetrexed in a homogeneous population. A secondary objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d086904482f640bbb8bb480f9cbada70
https://doi.org/10.1158/1078-0432.ccr-06-2377
https://doi.org/10.1158/1078-0432.ccr-06-2377
Autor:
Josep, Tabernero, Takayuki, Yoshino, Allen Lee, Cohn, Radka, Obermannova, Gyorgy, Bodoky, Rocio, Garcia-Carbonero, Tudor-Eliade, Ciuleanu, David C, Portnoy, Eric, Van Cutsem, Axel, Grothey, Jana, Prausová, Pilar, Garcia-Alfonso, Kentaro, Yamazaki, Philip R, Clingan, Sara, Lonardi, Tae Won, Kim, Lorinda, Simms, Shao-Chun, Chang, Federico, Nasroulah, Johanna, Bendell
Publikováno v:
The Lancet. Oncology. 16(5)
Summary Background Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF receptor 2. We assessed the efficacy and safety of ramucirumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf559ad12e50edf30d65f3fb304d08ad
https://pubmed.ncbi.nlm.nih.gov/26065608
https://pubmed.ncbi.nlm.nih.gov/26065608